NCT06868836 2026-05-18Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI TherapyShanghai Junshi Bioscience Co., Ltd.Phase 2 Recruiting78 enrolled